| Assessment Status | Awaiting full HTA submission from Applicant |
| HTA ID | 24035 |
| Drug | Dupilumab |
| Brand | Dupixent® |
| Indication | Dupilumab is indicated in adults as an add-on maintenance treatment for uncontrolled COPD characterised by raised blood eosinophils on a combination of an ICS, a LABA, and a LAMA, or on a combination of a LABA and a LAMA, if an ICS is not appropriate. |
| Assessment Process | |
| Rapid review commissioned | 06/09/2024 |
| Rapid review completed | 04/10/2024 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost-effectiveness of dupilumab for this indication compared with the current standard of care. |
| Full HTA commissioned by the HSE | 30/10/2024 |
| Pre-submission consultation with Applicant | 10/12/2024 |
The company has not submitted a HTA dossier to the NCPE, therefore the cost effectiveness of the technology could not be proven.